Seaport Therapeutics develops medicines that use its Glyph platform to route drugs through the gut’s lymphatic vessels, enhancing bioavailability while limiting systemic exposure. The company’s lead non-CNS program is GlyphCele, an investigational Glyphed oral prodrug of the COX-2 inhibitor celecoxib designed to restore gut lymphatic function implicated in metabolic diseases and pancreatic cancer. Preclinical studies show GlyphCele can repair lymphatic damage, improve metabolic markers, and potentially suppress tumor spread by delivering therapy directly to lymphatic tissue. While Seaport’s core pipeline remains focused on neuropsychiatric medicines, the firm is expanding the platform’s reach into metabolic and oncologic indications through external, non-dilutive funding. There are currently no approved oral drugs that directly target the lymphatic system, positioning Seaport to pioneer a new disease-modifying approach. The company recently secured up to $15 million in ARPA-H support, providing runway for continued preclinical and early clinical development; no revenue, user, or commercialization metrics were disclosed in the article.

Total raised

$340M

Funding rounds

3

Latest round

Grant

Latest activity

Mar 2026